Download Published Studies and Trial Excerpts Glutacyan/Sport Recovery Max

Published Studies and Trial Excerpts
Glutacyan/Sport Recovery Max
Reduced Glutathione Oral Supplement
(formerly Recancostat)
1. Up-regulation of interferon-gamma production by reduced glutathione,
anthocyane and L-cysteine treatment in children with allergic asthma and recurrent
respiratory diseases.
Negative correlation between serum IgE levels and production of IFN-gamma by
lymphocytes and positive correlation between serum IgE levels and production of IL4 by lymphocytes was detected in 12 children with allergic asthma and recurrent
respiratory diseases. Deficiency of reduced glutathione in whole blood and some
disorders in phagocytic and oxidative burst activity of monocytes were observed in
these children. Use of reduced glutathione, L-cysteine and anthocyane (Rec., Clear
Vision, Switzerland) resulted in elevation of IFN-gamma production, lymphocyte
response to mitogens, NK cell activity, increase in percentage of naive CD4(+) T
lymphocytes (refreshment effect) and improvement of clinical status. Positive clinical
results lasted 6 months.
Source: Chernyshov VP, Omelchenko LI, Treusch G, et al. Russ J Immunol. 2002
Apr;7(1):48-56.
2. Effects of Rec. Comp. on immune system on Chernobyl children with RRD.
Rec. Comp. (RC – tablets of reduced glutathione, l-cysteine, and anthyocane) were
used in the treatment of children (8-14 years old) with recurrent respiratory diseases
(RRD). Children lived on the territory with contamination of radionuclides after
Chernobyl accident. Before treatment levels of absolute number of CD3/CD4
lymphocytes, PHA-lymphocyte response, and activity of phagocytosis were
decreased. Levels of spontaneous NBT-test of blood neutrophils (without ex vivo
stimulation) were high. After RC treatment significant elevation to normal ranges of
numbers of CD3/CD4-lymphocytes, levels of PHA-stimulated lymphocyte response
and activity of phagocytosis were detected. Immediately after treatment, levels of
stimulated NBT-test were extremely low. But 5 months investigation confirmed
positive effect of RC: normal levels of spontaneous and stimulated NBT-test and
good levels of reserve were investigated. In temporary low levels of stimulated NBTtest immediately after treatment we suppose the mechanism of reduced
glutathione metabolism to react with free radicals. Positive immunological dynamics
correlated with good clinical effects.
1
Source: Chernyshov VP, Omelchenko LI, Treusch G, et al. Int J Immunorehabilitation.
May 1997;5:72.
3. Preliminary study of GSH L-cysteine anthocyane (Rec. Comp) in metastatic
colorectal carcinoma with relative denutrition.
Reduced glutathione (GSH) is a sulphur-containing nucleophile natural metabolic
molecule able to maintain cellular integrity and protect healthy cells against toxic
and radicalic compounds at physiological doses. Administered orally at high doses
GSH associated with both L-Cysteine Glutathione precursor and Anthocyane (Rec
Comp). The drug had been reported concerning a chemoprotection against tissue
toxicity of cytotoxic agents and multi-drug resistance. Also the drug may induce
inhibition of tumor growth in vitro and tumor regression with recovered nutrition and
weight in vivo (on rats).
A clinical trial had conducted in eleven (first group of multi-step Fleming evaluation
test) metastatic colorectal carcinomachemoresistant patients with various
denutrition phase and loss of weight. We report first clinical data for this study.
Treatment consisted in oral administration of 800 mg GSH twice a day for a minimum
of 90 days or until progression or toxicity (total dose: 144g GSH, 28.8 g L-cysteine, 23
g. Anthocyane). No drug related toxicities observed. Eight patients were evaluated.
All patients (8) are living (3-10 months) and the median duration of treatment was 21
weeks (11-33). Four patients recovered normal diet, high Karnowsky and increased
weight (three were able to return home), four patients had no response.
Conclusion: In addition of active therapeutic effect in cancer and
chemoprotection, Rec. Comp. maintains Karnowsky, nutrition, and weight of multitreated patients. Because no toxicity with Rec. Comp. at high doses, we will select
patients with cancer cachexia in second step of extended trial.
Source: Garcia-Giralt E, Pedereau B, Brixy F, et al. Presented at the European Cancer
Conference. September 14-18, 1997. Eur J Cancer. 1997:33(sup 8).
4. Immunological analysis of reduced glutathione, L-cysteine and anthocyane
effects in Chernobyl children with recurrent respiratory infections and chronic
inflammatory focal lesions.
Deficiency in glutathione system: decreased levels of reduced glutathione (GSH) in
plasma, whole blood; elevated intracellular levels of GSH in lymphocytes, and
especially in monocytes, were detected in 12 Chernobyl children with recurrent
respiratory infections (RRI) and chronic inflammatory focal lesions (CIFL group) in
2
comparison with 6 Chernobyl children with RRI only (placebo-controlled group) living
in the same territory contaminated by radionuclides. Deficiency in cytokine release
(TNF, IL-10, IL-12) by monocytes, in phagocytic function of neutrophils and
monocytes and disorders in oxidative burst activity of neutrophils and monocytes; as
some disorders in lymphocyte subsets were detected in CIFL
children in comparison to placebo-control group. Use of reduced glutathione, Lcysteine and anthocyane (Rec. Comp., Clear Vision, Switzerland) resulted in
normalization of immune status, glutathione balance (blood plasma and
intracellular levels of GSH), and improvement in clinical status. Frequency of acute
RRI per year decreased by 5.8 times in CIFL group of children and by 2 times in
placebo control group.
Source: Chernyshov VP, Omelchenko LI, Treusch G, et al. Cent Euro J Immunol.
2000;25(3):137-145.
5. Disorders in mononuclear phagocytes and reduced glutathione and their
correction in Chernobyl children with recurrent respiratory infections and chronic
inflammatory
Deficiency in glutathione system revealed by decreased levels of reduced
focal lesions.
glutathione (GSH) in blood plasma and in whole blood and elevated
intracellular levels of GSH in lymphocytes and especially in
mononuclear phagocytes were detected in 12 Chernobyl children with
recurrent respiratory infections (RRI) and chronic inflammatory focal
lesions: chronic bronchitis, gastroduodenitis, maxilla sinusitis, and
gastroesophageal reflux, (CIFL group of children) in comparison with six
Chernobyl children with RRI only – placebo-control (PC) group, living
in the same territory contaminated by radionuclides.
Deficiency of TNF, IL-10, IL-12 release after LPS stimulation of mononuclear
phagocytes were detected in CIFL group. Disorders in oxidative burst activity of
mononuclear phagocytes neutrophils were observed. Therapy by GSH, L-cysteine
and anthocyane resulted normalization (reconstitution_ of mononuclear
phagocytes and neutrophils function, glutathione balance (blood plasma and
intracellular levels of GSH) and improvement in clinical status. Elevated levels of
lymphocyte subsets CD3+CD8+CD38+, CD3+CD8+CD57+, CD19+CD5+ in CIFL group
decreased and reached levels of PC group. Proliferative response of T-lymphocytes
to anti-CD3 mAb increased after therapy. Frequency of acute RRI per year
decreased by 5.8 times after therapy in CIFL group and by 2 times in PC group of
children.
3
Source: Chernyshov VP, Omelchenko LI, Treusch G, et al. Abstracts of the 14th
European Immunology Meeting EFIS. September 23-27 2000. EFIS. 2000:73(2,3) :75302.
6. Refreshment effect of reduced glutathione, anthocyans and L-cysteine on
lymphocyte subsets and prevention of respiratory infections in Chernobyl children.
Objective: Analysis of immune mechanisms in prevention of recurrent respiratory
infections in children by Rec. Comp. treatment (tablets of reduced glutathione,
anthocyans and L-cysteine).
Method and Populations: IMK-lymphocyte and CD28 monoclonal antibodies were
used for two-color flow-cytometry. NK-cell activity, PHA and PWM proliferative
response, anti-thyroid antibodies, thyroid hormones and IgE were studied before,
after and 5 months after Rec. Comp. treatment in 11 Chernobyl children with
recurrent respiratory infections living on contaminated by radionuclides territory (5-15
Ci/km^2).
Results: Increase of CD28+/CD8+ lymphocyte levels, normalization of low NK-cell
activity and PHA-proliferative response and decrease of high IgE levels,
normalization of high levels of absolute counts and percentage of activate Tlymphocytes bearing HLA DR marker (CD3+/HLA DR+) especially in more heavy
cases and complicated with anti-thyroid antibodies were detected after Rec.
Comp. treatment. There was positive clinical effect during 5 months after treatment.
Conclusion: Reduced glutathione, anthocyans, and L-cysteine in combined using
have refreshment effect on lymphocyte subsets that prevent respiratory infections in
immunocompromized Chernobyl children.
Source:Chernyshov VP, Omelchenko LI, Treusch G, et al. Programs and Abstracts of
the 5th International Conference on the Prevention of Infection. May 6-7, 1998.
NICE. 1998.
7. Disorders in GSH, phagocytosis and monocyte production of TNF, IL-10, IL-12 in
children with RRD complicated by allergy and chronic inflammatory focal lesions.
4
Deficiency of reduced glutathione (GSH) in whole blood of children with
recurrent respiratory disorders (RRD) complicated by allergy (A) and
chronic inflammatory focal lesions (CIFL) was detected. RRD patients
without complications were as placebo-control group (PC). 42 Chernobyl
children living on territory contaminated by radionuclides were included into
study.
Elevated percentage of phagocytosis but decreased phagocytosis intensity in
neutrophils and monocytes were detected in A and CIFL patients. In CIFL but not in
A patients percentage of neutrophils with oxidative burst activity after stimulation by
fMLP and E.coli was elevated but intensity of oxidative burst was elevated in both
groups. Deficiency of release of TNF, IL-10, IL-13 by monocytes was detected in A
and CIFL patients. Therapy by Rec. Comp. (GSH, L-cysteine, anthocyane) resulted
normalization in phagocytosis and intracellular ingesting of neutrophils and
monocytes, GSH balance and improvement in clinical status. In CIFL children
cytokine production was normalized. Positive clinical effect of therapy in A group
during 0.5 year and in CIFL group during one year was registered.
Source: Chernyshov VP, Omelchenko LI, Treusch G, et al. Abstracts of the 14th
International Congress of Immunology. July 24, 2001. Scandinavian J Immunol.
July/August 2001:54(Supp. 1).
8. An alternative for skin care during external radiation beam radiation.
Objective: Skin reaction during radiation therapy for breast malignancy can result in
significant discomfort and desquamation which may necessitate delays in therapy.
Rreduced glutathione (GSH) and anthocyanins are natural antioxidants with
transdermal absorption noted to dramatically decrease the observed skin reaction
during radiotherapy (XRT) in a few patients treated in our department. This spurred us
to undertake an objective evaluation of their effectiveness.
Methods: Patients undergoing whole breast external beam irradiation were
randomized to receive either placebo or GSH/anthyyanins one to three hours before
daily therapy over their 6 weeks course of treatment. Standard skin care of Vitamin E
oil and Aloe Vera was used in both groups. Patients and investigators/staff were
blinded. Skin reaction was documented by photographs and a severity scale.
5
Results: Thirty two (32) patients were enrolled. Thirty (30) were evaluable. Fifteen (15)
received placebo, 15 GSH/anthocyanins. Scores were calculated by percent of
breast skin involved and grade of reaction. The group receiving GSH/anthocyanins
had a lower average score, 93.67 vs the placebo groups 123.33. This translated to an
average severity score in the GSH/anthocyanins group 24% less than that seen in the
placebo group. Small group numbers for the pilot trial did not reach statistical
significance (p > .05), but showed a trend in favor of GSH/anthocyanins.
Conclusion: GSH/anthocyanins can provide skin protection during XRT which
supercedes that observed with standard skin care and placebo. This formula may
reduce discomfort associated with breast irradiation.
Source: Enomoto TM, Johnson T, Petersen N, Homer L, Walts D, Johnson N. Presented
at the Portland Surgical Society Annual Scientific Meeting (2003) and the North
Pacific Surgical Association Annual Meeting (2004) .
Unpublished studies
9. Peterson N. Benefit of GSH for prevention of radiation burn associated with external
beam radiation therapy. Center for Traditional Medicine. Lake Oswego, Oregon.
REFERENCES
1.
The role of glutathione in combination with cisplatin in the treatment of
ovarian cancer, Tedeschi, M; De Cesare, A.; Oriania, S.; Perego, P.; Silva, A.;
Venturino, P.; Zunino, F.; Cancer Treatment Reviews (1991) 18, 253-259
2.
Reduced Glutathione Protects against Cisplatin-induced Neurotoxicity in
Rats, Hamers, F.P.T.; Brakkee, J.H.; Cavalletti, E.; Tedeschi, M.; Marmonti, L.; Pezzoni,
G.; Neijt, J.P.; Gipsen, W.H.; Cancer Research 53, 544-549, February 1, (1993)
3.
Protective effect of reduced glutathione against cisplatin induced renal and
systemic toxicity and its influence on the therapeutic activity of antitumor drug,
Zunino, F.; Pratesi, G.; Micheloni, A.; Cavalletti, E.; Sala, F.; Tofanetti, O.; Chem.-Biol.
Interactions, 70 (1989) 89-101, Elsevier Scientific Publishers Ireland Ltd.
4.
Prevention of cyclophosphamide-induced urotoxicity by reduced glutathione
and its effect on acute toxicity and antitumor activity of the alkylating agent,
Tofanetti, O.; Cavalletti, E.; Besati, A.; Pratesi, G.; Pezzoni, G.; Zunino, F.; Cancer
Chemother. Pharmacol. (1985) 14: 188-193
5.
Prevention of Doxorubicin Myocardial Toxicity in Mice by Reduced
6
Glutathione, Yoda, Y.; Nakazawa, M.; Abe, T.; Kawakami, Z.; Cancer Research 46,
2551-2556, May (1986)
6.
Influence of glutathione administration on the disposition of free and total
platinum in patients after administration of cisplatin, Leone, R.; Fracasso, M.E.; Soresi,
E.; Cimino, G.; Tedeschi, M.; Castoldi, D.; Monzani, V.; Colombi, L.; Usari, T.;
Bernareggi, A.; Cancer Chemother. Pharmacol. (1992) 29: 385-390
7.
Phase I Trial of Cisplatin in Combination with Glutathion, Plaxe, St.; Freddo, J.;
Kim, S.; Kirmani, S.; McClay, E.; Christen, R.; Braly, P.; Howell, St.; Gynecology
Oncology 55, 82-86 (1994)
8.
Weekly 5-fluorouracil and folinic acid plus escalating doses of cisplatin with
glutathione protection in patients with advanced head and neck cancer, Gebbia,
V.; Valenza, R.; Testa, A.; Zerillo, G.; Restivo, S.; Cupido, G.; Ingria, F.; Spadafora, F.;
Barbaccia, C.; Cannata, G.; Cipolla, C.; Gebbia, N.; Med. Oncol. & Pharmacother.
Vol. 9 No. 4 pp. 165-168, (1992)
9.
A phase II study of combination chemotherapy in advanced ovarian
carcinoma with cisplatin and cyclophosphamide plus reduced glutathione as
potential protective agent against cisplatin toxicity, Locatelli, M.C.;D´Antona, A.;
Labianca, R.; Vinci, M.; Tedeschi, M.; Carcione, R.; Corbo, A.; Venturino, P.; Luporini,
G.; Tumori, 79: 37-39 (1993)
10.
Efficacy and safety of high-dose cisplatin and cyclophosphamide with
glutathione protection in the treatment of bulky advanced epithelial ovarian
cancer, Di Re, F.; Bohm, S.; Oriana, S.; Spatti, G.B.; Zunino, F.; Cancer Chemother.
Pharmacol. (1990) 25: 355-360
11.
A preliminary clinical study of cyclophosphamide with reduced glutathione
as uroprotector, Nobile, M.T.; Vidili, M.G.; Benasso, M.; Venturini, M.; Tedeschi, M.;
Zunino, F.; Rosso, R.; Tumori, 75: 257-258, (1989)
12.
Reduced glutathione and S-acethylglutathione as selective appoptosisinducing agents in cancer therapy, Donnerstag, B.; Ohlenschläger, G.; Cinatl, J.;
Amrani, M.; Hofmann, D.; Flindt, S.; Treusch, G.; Träger, L.; Elsevier, Cancer Letters 110
(1996) 63-70
13.
Glutathione augments the activation of cytotoxic T-lymphocytes in vivo,
Dröge, W.; Pottmeyer-Gerber, Ch.; Schmidt, H.; Nick, S.; Immunobiol., Vol. 172, pp.
151-156 (1986)
14.
Studie über die Wirkung von GSH, L-Cystein und Anthocyanen (Recancostat®
7
Comp.) bei metastatischem kolorektalem Karzinom mit relativer Mangelernährung,
Garcia-Giralt, E.; Perdereau, B.; Brixy, F.; Rhilouch, H.; Treusch, G.; Ohlenschläger, G.;
Pouillart, P.; Seventh International Congress on Anti-Cancer Treatment, 3.-6.02.1997
15.
Attestation, Perdereau, B.; Institut Curie, Section médicale et hospitaliére,
5.7.1999
16.
Refreshment effect of reduced glutathione, anthocyans and L-cystein on
lymphocyte subsets and prevention of respiratory infections in chernobyl children,
Chernyshov, V.; Omelchenko, L.; Treusch, G.; Vodyanik, M.; Vykhovanets, E.;
Pochinok, T.; Institut of Pediatrics, Obstetrics and Gynecology, Academy of Medical
Sciences, Kiev; 5th International Conference on the Prevention of Infection, May 6th7th 1998 Acropolis Nice (France)
17.
Disorders in mononuclear phagocytes and reduced glutathione and their
correction in Chernobyl children with recurrent respiratory infections and chronic
inflammatory focal lesions, Chernyshov, V.P.; Omelchenko, L.I.; Treusch, G.;
Vodyanik, M.A.; Pochinok, T.V.; Zelinsky, G.M.; Gumenyuk, M.V.; Institut of Pediatrics,
Obstetrics and Gynecology, Academy of Medical Sciences, Kiev; Elsevier,
Immunology Letters, Vol. 73, No. 2,3 73 75-302, Abstract No. 523, Abstracts of the 14th
European Immunology Meeting EFIS 2000, 23.-27.09.2000
18.
Immunological analysis of reduced glutathione, L-cystein and Anthocyane
effects in Chernobyl children with recurrent respiratory infections and chronic
inflammatory focal lesions, Chernyshov, V.P.; Omelchenko, L.I.; Treusch, G.;
Vodyanik, M.A.; Pochinok, T.V.; Zelinsky, G.M.; Gumenyuk, M.V.; Institut of Pediatrics,
Obstetrics and Gynecology, Academy of Medical Sciences, Kiev; Central European
Journal of Immunology, Vol. 25, 3-2000
19.
Glutathion treatment of hepatocellular carcinoma, Dalhoff, K.; Ranek, L.;
Mantoni, M.; Poulsen, H.E.; University of Copenhagen; Liver 1992: 12: 341-343,
Munksgaard (1992)
20.
Redox Recycling between Glutathione and Anthocyans in Vitro,
Ohlenschläger, G.;Treusch, G.;
21.
Suppression of Tumor Cell Growth by Anthocyanins in Vitro, Kamei, H.; Kojima,
T.; Hasegawa, M.; Koide, T.; Umeda, T.; Yukawa, T.; Terabe, K.; Cancer Investigation,
13(6), 590-594 (1995), Marcel Dekker, Inc.
22.
Flavonoide-Mediated Tumor Growth Suppression Demonstrated by in vivo
Study, Kamei, H.; Tatsurou, K.; Kojimam, T.; Hasegawa, M.; Umeda, T.; Terabe, K.;
Hashimoto, Y.; Cancer Biotherapy & Radiopharmaceuticals, Vol. 11, No. 3 (1996)
8
Mary Ann Liebert, Inc.
23.
Reduced glutathione and anthocyans – Redox-cycling and redox-recycling
in bioloogical systems, Ohlenschläger, G.; Treusch, G.; Praxis-Telegramm, Special
Edition, Supplement to issue No. 6/94, December 1994, Ralf Reglin Verlag, Köln
24.
Lexikon der Biochemie und Molekularbiologie; Herder Verlag, Band 2, 1992
9